Last reviewed · How we verify

Nulojix — Competitive Intelligence Brief

Nulojix (BELATACEPT) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective T Cell Costimulation Blocker [EPC]. Area: Immunology.

marketed Selective T Cell Costimulation Blocker [EPC] T-lymphocyte activation antigen CD80 Immunology Recombinant protein Live · refreshed every 30 min

Target snapshot

Nulojix (BELATACEPT) — Bristol-Myers Squibb. Nulojix blocks the activation of T cells by binding to CD80, preventing an immune response.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Nulojix TARGET BELATACEPT Bristol-Myers Squibb marketed Selective T Cell Costimulation Blocker [EPC] T-lymphocyte activation antigen CD80 2011-01-01
Nulojix Nulojix Bristol-Myers Squibb marketed T-lymphocyte activation antigen CD80, T-lymphocyte activation antigen CD86
Orencia Orencia Bristol-Myers Squibb marketed T-lymphocyte activation antigen CD80, T-lymphocyte activation antigen CD86

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective T Cell Costimulation Blocker [EPC] class)

  1. Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nulojix — Competitive Intelligence Brief. https://druglandscape.com/ci/belatacept. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: